[20120314. Complications of EMR/ESD (69): Bleeding (33) - warfarin (1) Mr. PG]
¿À´ÃºÎÅÍ´Â ¿ÍÆĸ° °ü·Ã À̽´¸¦ ´Ù·ç°Ú½À´Ï´Ù.
¿ì¼± ¾î¶² °¨»çÀÇ ±ÛÀ» ¼Ò°³ÇÕ´Ï´Ù (Miller 1999). Acknowledgement´Â ³í¹®À̳ª ¸®ºä¸¦ ¾²´Âµ¥ µµ¿òÀ» ÁØ ½º½Â ȤÀº µ¿·á¿¡°Ô °¨»çÀÇ ¶æÀ» ÀüÇÏ´Â °ø°£ÀÔ´Ï´Ù. ȯÀÚ¸¦ ¾ð±ÞÇÏ´Â °ÍÀº ¹«Ã´ ÀÌ·ÊÀûÀÔ´Ï´Ù. Miller¶ó´Â ÀúÀÚ°¡ Mr. PG¶ó´Â ȯÀÚ¿¡°Ô °¨»ç¸¦ Ç¥ÇÏ°í ÀÖ½À´Ï´Ù. Dr. PG°¡ ¾Æ´Ï°í Mr. PGÀÔ´Ï´Ù.
±×·±µ¥ acknowledgementÀÇ ³»¿ëÀÌ Ãæ°ÝÀûÀÔ´Ï´Ù. "The authors wish to dedicate this article to Mr PG, who died following a serious thromboembolic complication during preparation for an endoscopic procedure." ³»½Ã°æÀ» ÁغñÇÏ´ø Áß »ç¸ÁÇÑ PG ¾¾¿¡°Ô ¸®ºä¸¦ ¹ÙÄ£´Ù´Â ³»¿ëÀÔ´Ï´Ù. ȯÀÚ°¡ Á×°í³ ÈÄ¿¡¾ß °ü·Ã ºÐ¾ß¸¦ °øºÎÇÏ¿© Àü¹®°¡°¡ µÇ¾ú´Ù´Â °ÍÀϱî¿ä?
ÇÕº´ÁõÀº ³²ÀÇ ÀÏó·³ ´À²¸Áö±â ½±½À´Ï´Ù. ±×·¯³ª ²À ±×·¸°Ô º¼ Àϵµ ¾Æ´Õ´Ï´Ù. ù ÇÕº´ÁõÀÌ »ç¸ÁÀÏ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ¿ì¸®´Â °£Á¢ °æÇèÀ¸·ÎºÎÅÍ ¹º°¡¸¦ ¹è¿ö¾ß ÇÕ´Ï´Ù. Á÷Á¢ °æÇèÇϱâ Àü ÀûÀýÇÑ risk sensingÀÌ ÇÊ¿äÇÕ´Ï´Ù.
¹®Çå¿¡¼´Â ¾àÀ» ¿À·¡ ²÷Áö ¸»µµ·Ï ±ÇÇÏ°í ÀÖ½À´Ï´Ù. ÀÏ°üµÈ ±Ç°íÀÔ´Ï´Ù. ¹«½ÃÇÏÁö ¸¿½Ã´Ù.
2) Ç×Ç÷¼ÒÆÇÁ¦ Antiplatelets - ³»½Ã°æ ȤÀº Á¶Á÷°Ë»ç Àü ¾Æ½ºÇǸ°, Ç×Ç÷¼ÒÆÇÁ¦¸¦ ²÷À» °ÍÀΰ¡?
3) »õ·Î¿î Ç×ÀÀ°íÁ¦ New oral anticoagulant (NOAC)
4) Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦ Áß´Ü Áöħ (»ï¼º¼¿ïº´¿ø 2011)
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà